Inclusion Criteria:

- Male and female subjects ≥18 years of age

- Signed written informed consent

- Histologically or cytologically documented metastatic or locally advanced
survivin-expressing solid tumor for which no established therapy exists

- Disease must be measurable by RECIST criteria or evaluable by clinical, radiographic,
or laboratory criteria established for the given tumor entity

- Expressing at least one of the following HLA alleles:HLA-A1,-A2,-A3,-A24, and -B7
assessed by HLAgenotyping

- ECOG performance status of ≤1, estimated life expectancy of at least 3 months

- Adequate hematological function defined by WBC ≥3 x 10x9/L, lymphocyte count ≥0.5 x
10x9/L, hemoglobin ≥10 g/dL, platelet count ≥100 x 10x9/L

- Adequate blood coagulation parameters defined as aPTT and INR ≤ 1.5 x ULN

- Adequate renal function defined by a serum creatinine ≤2 x ULN

- Adequate hepatic function defined by total bilirubin ≤2 x ULN and AST and ALT levels
≤2.5 x ULN (in subjects with liver metastases ≤5 x ULN)

- Effective contraception for female and male subjects if the risk of conception exists

Exclusion Criteria:

- Treatment in another clinical study within the past 30 days prior to the first
administration of study treatment

- Previous treatment with an investigational anticancer vaccine

- Requirement of concurrent treatment with a nonpermitted drug

- Active significant autoimmune disease (with the exception of vitiligo)

- Receipt of allogeneic stem cell transplantation

- Significant acute or chronic infections (e.g. viral hepatitis, HIV)

- Primary brain tumors and brain metastases (with the exception of brain metastases
that are stable after irradiation or surgically resected brain metastases if subjects
have been asymptomatic for ≥6 months)

- Rapidly progressive disease (e.g. tumor lysis syndrome)

- Radiotherapy, chemotherapy, surgery (excluding prior diagnostic biopsy),
immunotherapy or any investigational drug within 30 days before the start of study
treatment

- Pregnancy or lactation

- Active drug or alcohol abuse

- Known hypersensitivity to the study treatment or any of its components

- Any significant disease that, in the Investigator's opinion, should exclude the
subject from the study; for questions about this criterion, the Investigator should
contact the sponsor.

- Persisting toxicity related to prior therapy ≥grade 2 National Cancer
Institute-Common Terminology Criteria For Adverse Events version 3.0

- Legal incapacity or limited legal capacity